A composition for protecting cardiovascular and a method for manufacturing the same

Abstract

This invention belongs to the field of food science and technology, specifically relating to a composition for cardiovascular protection and its preparation method. The composition includes freeze-dried natto powder, milk protein peptide powder, dihydromyricetin, and functional red yeast rice powder. The freeze-dried natto powder has a nattokinase content of 3000 FU / g, 5000 FU / g, 10000 FU / g, or 20000 FU / g. The milk protein peptide powder has a total VPP and IPP content ≥5.0%, and the milk protein peptide powder has an ACE inhibition rate ≥63%. This invention addresses the limitations of existing cardiovascular health foods that rely on single-component efficacy and cannot achieve multi-target, comprehensive protection. It employs a scientific combination of four natural active ingredients—freeze-dried natto powder, milk protein peptide powder, dihydromyricetin, and functional red yeast rice powder—to achieve synergistic effects across multiple targets.

Description

Technical Field

[0001] This invention belongs to the field of food science and technology, specifically relating to a composition for protecting the cardiovascular system and its preparation method. Background Technology

[0002] With the accelerating aging of the population and the high-fat, high-sugar diets and sedentary lifestyles of contemporary people, the incidence of cardiovascular-related health problems such as hypertension, hyperlipidemia, thrombosis, and vascular endothelial damage is rising year by year, becoming a major global public health challenge that seriously threatens human life and health. The pathogenesis of cardiovascular diseases is complex, mainly related to the synergistic effects of multiple factors such as decreased vascular elasticity, dyslipidemia, vascular endothelial dysfunction, and thrombus accumulation. Its onset is insidious, its course is long, and long-term clinical drug intervention is prone to drug resistance and side effects such as liver and kidney damage. Therefore, developing safe, effective, and side-effect-free natural health foods for the prevention and adjuvant improvement of cardiovascular health, and addressing the shortcomings of existing intervention methods, has become a pressing technical challenge in the current health food field, and a research hotspot and urgent need for those skilled in the art.

[0003] Currently, there are many types of health foods on the market for protecting the cardiovascular system, but most products suffer from technical defects such as unreasonable formula design, limited effects of single ingredients, and single efficacy, making it difficult to achieve multi-target and comprehensive cardiovascular protection effects and failing to meet the actual needs of clinical and daily health care. Summary of the Invention

[0004] The purpose of this invention is to provide a method for preparing a composition for protecting the cardiovascular system, thereby solving the problems mentioned in the background art.

[0005] To achieve the above objectives, the present invention provides the following technical solution: a composition for protecting the cardiovascular system, comprising natto freeze-dried powder, milk protein peptide powder, dihydromyricetin, and functional red yeast rice powder;

[0006] The natto freeze-dried powder has a nattokinase content of 3000 FU / g, 5000 FU / g, 10000 FU / g or 20000 FU / g, the total content of VPP and IPP in the milk protein peptide powder is ≥5.0%, and the inhibition rate of the milk protein peptide powder against ACE is ≥63%.

[0007] Preferably, by weight parts, the composition comprises 10-50 parts of natto freeze-dried powder, 5-30 parts of milk protein peptide powder, 1-10 parts of dihydromyricetin, and 5-25 parts of functional red yeast rice powder.

[0008] Preferably, the natto freeze-dried powder is obtained by solid-state fermentation and vacuum freeze-drying of natto bacteria; the milk protein peptide powder is obtained by enzymatic hydrolysis, inactivation, filtration, concentration, sterilization and spray drying of milk powder or casein as raw materials; and the functional red yeast rice powder is a product obtained by fermenting rice with Monascus purpureus rich in Monascus K.

[0009] Preferably, the dihydromyricetin is derived from the fruit of the Japanese raisin tree.

[0010] The present invention also provides a method for preparing the composition for protecting the cardiovascular system, comprising the following steps:

[0011] S1. Raw material pretreatment: The freeze-dried natto powder, milk protein peptide powder, dihydromyricetin, and functional red yeast rice powder are sieved separately to remove impurities and set aside.

[0012] S2. Mixing: The pretreated natto freeze-dried powder, milk protein peptide powder, dihydromyricetin, and functional red yeast rice powder are added into the mixing equipment in proportion and mixed evenly to obtain a mixture.

[0013] S3. Post-processing: The mixture obtained in step S2 is subjected to secondary sieving and metal detection. After passing the test, the composition for protecting the cardiovascular system is obtained.

[0014] Preferably, in step S1, the sieving is done through a 2.5mm sieve; in step S3, the secondary sieving is performed using a 60-mesh sieve produced from food raw materials for fine sieving.

[0015] Preferably, in step S2, the mixing device is a high-efficiency mixer with a mixing speed of 100-300 r / min and a mixing time of 10-30 min.

[0016] Preferably, in step S3, the metal detection involves passing the mixture through a metal detector to detect that the size of the iron-containing metal foreign matter is <2.0 mm and that no metal foreign matter exceeds the control index.

[0017] The present invention further provides the application of the composition in the preparation of health foods that protect vascular endothelium, dissolve thrombi, regulate blood lipids, improve vascular elasticity, or regulate blood pressure.

[0018] Preferably, the health food is in the form of at least one of capsules, tablets, compressed candies, and solid beverages.

[0019] Compared with the prior art, the beneficial effects of the present invention are:

[0020] 1. This invention addresses the limitations of existing cardiovascular health foods that rely on single-ingredient efficacy and cannot achieve comprehensive protection against multiple targets. It scientifically combines four natural active ingredients—natto freeze-dried powder, milk protein peptide powder, dihydromyricetin, and functional red yeast rice powder—to achieve synergistic effects against multiple targets, effectively overcoming the shortcomings of existing products. Specifically, nattokinase in the natto freeze-dried powder can efficiently dissolve thrombi and prevent thrombus accumulation, specifically addressing the problem of thrombus formation; the milk protein peptide powder (with a clearly defined total VPP and IPP content ≥ 5.0% and ACE inhibition rate...) (≥63%) can effectively inhibit ACE activity, protect vascular endothelium, regulate blood pressure, and precisely improve vascular endothelial function and blood pressure levels; dihydromyricetin (derived from Hovenia dulcis) has significant antioxidant and anti-inflammatory effects, which can effectively improve vascular elasticity; Monacolin K in functional red yeast rice powder can efficiently regulate blood lipids and improve lipid metabolism disorders. The four work synergistically to achieve comprehensive cardiovascular protection effects, including protecting vascular endothelium, dissolving thrombi, regulating blood lipids, improving vascular elasticity, and regulating blood pressure. The efficacy is comprehensive and significant, solving the technical problem of single efficacy in existing products. Attached Figure Description

[0021] Figure 1 This is a schematic diagram of steps S1-S3 of the preparation process of a composition for protecting the cardiovascular system according to the present invention;

[0022] Figure 2 This is a bar chart comparing the inhibitory activity of milk protein peptide powder against ACE in this invention; it shows the inhibition rate of two batches.

[0023] Figure 3 This invention compares the effect of milk protein peptide powder on the blood vessel diameter of zebrafish between the control group and the treatment group.

[0024] Figure 4 This is a comparison of fluorescence intensity of the effect of milk protein peptide powder on NO fluorescence staining intensity in zebrafish in this invention;

[0025] Figure 5 This is a graph showing the effect of milk protein peptide powder on the expression of the ACE gene in zebrafish, comparing gene expression levels.

[0026] Figure 6 This is a comparison chart showing the improvement of core clinical indicators in humans using the milk protein peptide compressed candy of the present invention. Detailed Implementation

[0027] The technical solutions of the embodiments of the present invention will be clearly and completely described below with reference to the accompanying drawings. Obviously, the described embodiments are only some embodiments of the present invention, and not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of the present invention.

[0028] Example 1: Preparation and Activity Testing of Milk Protein Peptide Powder

[0029] 1.1. Preparation of milk protein peptide powder

[0030] Take 100 kg of milk powder, add an appropriate amount of water to dissolve it, adjust the pH to a suitable value, add protease for enzymatic hydrolysis, and the enzymatic hydrolysis conditions are: temperature 50-55℃, time 4-6 hours; after the enzymatic hydrolysis is completed, heat up to inactivate, filter to remove insoluble matter, and concentrate, sterilize and spray dry the filtrate to obtain milk protein peptide powder.

[0031] 1.2. Detection of VPP and IPP content

[0032] The contents of VPP and IPP in milk protein peptide powder were determined by high performance liquid chromatography-mass spectrometry (HPLC-MS). Chromatographic conditions: C18 column (4.6×250mm, 5μm), mobile phase: acetonitrile-water (containing 0.1% formic acid), gradient elution, flow rate: 1.0mL / min, detection wavelength: 214nm; Mass spectrometry conditions: electrospray ionization (ESI), positive ion mode, scan range: m / z 100-500.

[0033] Test results: VPP content was 3.2%, IPP content was 2.8%, and the total VPP and IPP content was 6.0%, which meets the requirement of ≥5.0%.

[0034] 1.3. ACE Inhibitory Activity Detection

[0035] The method was adapted from that of Cushman DW et al. (Biochemical Pharmacology, 1971, 20(7):1637-1648).

[0036] Method Principle: Hippuric acid (Hip) is hydrolyzed by ACE in the presence of ACE inhibitors. The amount of hippuric acid produced decreases when an ACE inhibitor is added. The peak area of ​​hippuric acid at 228 nm is determined by high-performance liquid chromatography (HPLC), and the ACE inhibition rate is calculated.

[0037] Operating steps:

[0038] Prepare a 5 mmol / L HCl solution (dissolved in a 0.1 mol / L borate buffer solution containing 0.3 mol / L NaCl, pH 8.3).

[0039] Prepare a 0.1 U / mL ACE solution (diluted with 0.1 mol / L borate buffer containing 0.3 mol / L NaCl);

[0040] Take 80 μL of HHL solution, add 20 μL of sample, and incubate at 37 °C for 5 min;

[0041] Add 20 μL of ACE solution and incubate at 37°C for 30 min;

[0042] The reaction was terminated by adding 200 μL of 1 mol / L HCl.

[0043] Samples were analyzed after filtration through a 0.45 μm filter membrane.

[0044] Test results: The inhibition rate of milk protein peptide powder on ACE was 64.5%, which meets the requirement of ≥63%.

[0045] Example 2: Extraction of dihydromyricetin from Hovenia dulcis seeds

[0046] Take 10 kg of dried Hovenia dulcis seeds, crush them through a 40-mesh sieve, add 10 times the amount of 60% ethanol aqueous solution, reflux for 2 hours, and filter. Add 8 times the amount of 60% ethanol aqueous solution to the filter residue, reflux for 1.5 hours, and filter. Combine the two filtrates, concentrate under reduced pressure to a relative density of 1.10–1.15 (60℃), refrigerate for 24 hours to separate the layers, centrifuge the supernatant, and spray dry to obtain Hovenia dulcis extract.

[0047] HPLC analysis showed that the extract contained 12.5% ​​dihydromyricetin; this extract can be used as a source of dihydromyricetin in the compositions of this invention.

[0048] Example 3: Preparation of Natto Freeze-Dried Powder

[0049] Selected soybeans are washed, soaked, steamed, and cooled to about 40°C. They are then inoculated with imported Japanese natto bacteria and fermented in a solid state at 37-42°C for 20-24 hours. After fermentation, the material is frozen to below -30°C, then vacuum freeze-dried, pulverized, and sieved to obtain freeze-dried natto powder.

[0050] Tests showed that the natto kinase content in the freeze-dried natto powder was 20,000 FU / g.

[0051] Example 4: Preparation of Functional Red Yeast Rice Powder

[0052] Take rice, wash and soak it, then steam and cook it. After cooling, inoculate it with Monascus purpureus and ferment it in a solid state at 25-30℃ for 10-15 days. After fermentation, dry and crush the material to obtain functional red yeast rice powder.

[0053] Tests showed that the monacolin K content in functional red yeast rice powder was 3.5%.

[0054] Example 5: Figure 1 As shown, the composition of the present invention is prepared (Formula 1).

[0055] Take each raw material according to the following parts by weight:

[0056] 20 portions of freeze-dried natto powder (nattokinase content 20000FU / g);

[0057] 15 portions of milk protein peptide powder (total VPP+IPP content 6.0%, ACE inhibition rate 64.5%);

[0058] Five samples of dihydromyricetin (content 12.5%) derived from Hovenia dulcis seeds;

[0059] Functional red yeast rice powder (monacolin K content 3.5%) 12 portions.

[0060] Preparation method:

[0061] S1. Raw material pretreatment: Pass the above four raw materials through a 2.5mm sieve to remove impurities and set aside for later use;

[0062] S2. Mixing: The four pretreated raw materials are put into a high-efficiency mixer, the mixing speed is set to 200 r / min, the mixing time is 20 min, and the mixture is uniformly mixed to obtain a mixture.

[0063] S3. Post-processing: The mixture obtained in step S2 is subjected to a second sieve (using a 60-mesh sieve) and metal detection (detection standard: iron-containing metal foreign matter size < 2.0 mm). After passing the detection, the composition of the present invention is obtained.

[0064] Example 6: As Figure 1 As shown, the composition of the present invention is prepared (Formula 2).

[0065] Take each raw material according to the following parts by weight:

[0066] 10 portions of freeze-dried natto powder (nattokinase content 10000FU / g);

[0067] Five portions of milk protein peptide powder (total VPP+IPP content 5.8%, ACE inhibition rate 63.5%);

[0068] One part of dihydromyricetin (content 12.5%) derived from Hovenia dulcis seeds;

[0069] Five portions of functional red yeast rice powder (monacolin K content 3.5%).

[0070] The preparation method is the same as in Example 5.

[0071] Example 7: Figure 1 As shown, the composition of the present invention is prepared (Formula 3).

[0072] Take each raw material according to the following parts by weight:

[0073] 50 portions of freeze-dried natto powder (nattokinase content 10000FU / g);

[0074] 30 portions of milk protein peptide powder (total VPP+IPP content 5.8%, ACE inhibition rate 63.5%);

[0075] Ten samples of dihydromyricetin (content 12.5%) derived from Hovenia dulcis seeds;

[0076] Functional red yeast rice powder (monacolin K content 3.5%) 25 portions.

[0077] The preparation method is the same as in Example 5.

[0078] Experimental Example 1: Figure 2 As shown, the ACE inhibitory activity of milk protein peptide powder was detected.

[0079] 1.1 Test Materials

[0080] Sample 1: Milk protein peptide powder (batch number: 101988), provided by Yangling Cuijian Biotechnology Co., Ltd.;

[0081] Sample 2: Milk protein peptide powder (batch number: 20220601), provided by Yangling Cuijian Biotechnology Co., Ltd.;

[0082] ACE enzyme (0.25U / vial), Sigma-Aldrich;

[0083] HHL substrate, Sigma.

[0084] 1.2. Test Methods

[0085] Same as Example 1.3.

[0086] 1.3. Test Results

[0087] Sample 1: Milk protein peptide powder, batch number 101988, ACE inhibition rate 65.13%.

[0088] Sample 2: Milk protein peptide powder, batch number 20220601, ACE inhibition rate 63.27%.

[0089] The results showed that the milk protein peptide powder used in this invention had an ACE inhibition rate of ≥63%, which meets the requirements of the claims.

[0090] Experimental Example 2: Protective Effect of Milk Protein Peptide Powder on Vascular Endothelial Injury in Zebrafish

[0091] 2.1. Test Materials

[0092] Milk protein peptide powder (batch number: 20220601) was provided by Yangling Cuijian Bioengineering Technology Co., Ltd.

[0093] Zebrafish (AB strain), provided by Hangzhou White Biotechnology.

[0094] 2.2. Test Methods

[0095] The procedure was performed according to the standard operating procedures of Hangzhou White Biotechnology Co., Ltd. A zebrafish model of vascular endothelial injury was established, and different concentrations of milk protein peptide powder were administered. Blood vessel diameter, NO fluorescence staining intensity, and relative expression levels of the ace gene were measured.

[0096] 2.3. Test Results

[0097] 2.3.1. For example Figure 3 As shown, the effect on blood vessel diameter:

[0098] Compared with the model control group, the diameter of blood vessels in zebrafish treated with milk protein peptide powder was significantly increased (***p<0.001), indicating that milk protein peptide powder has the effect of protecting vascular endothelium and improving vascular structure.

[0099] 2.3.2 such as Figure 4 As shown, the effect on NO fluorescence staining intensity

[0100] Compared with the model control group, the NO fluorescence staining intensity of zebrafish treated with milk protein peptide powder was significantly enhanced (**p<0.01, ***p<0.001), indicating that milk protein peptide powder can promote NO synthesis in vascular endothelial cells and improve vascular function.

[0101] 2.3.3. For example Figure 5 As shown, the effect on ace gene expression

[0102] Compared with the model control group, the relative expression level of the ACE gene in zebrafish treated with milk protein peptide powder was significantly downregulated (**p<0.01, ***p<0.001), indicating that milk protein peptide powder can inhibit ACE expression at the gene level and exert a blood pressure-lowering effect.

[0103] 2.4. Experimental Conclusions

[0104] Under the experimental conditions, milk protein peptide powder has a protective effect against vascular endothelial injury, specifically by increasing the intensity of NO fluorescence staining, increasing the diameter of blood vessels, and downregulating the relative expression level of the ace gene.

[0105] Experimental Example 3: Figure 6 As shown, the human clinical efficacy verification of milk protein peptide compressed candy.

[0106] This experiment used the milk protein peptide powder (total VPP+IPP content ≥5.0%, ACE inhibition rate ≥63%) from the composition of this invention to prepare milk protein peptide compressed candy. Three subjects with abnormal cardiovascular indicators were selected for clinical trial. None of the subjects had serious liver or kidney dysfunction and had not taken other lipid-regulating / hypertensive health foods or drugs. They took 2.5g of milk protein peptide compressed candy daily for 45–55 days. Triglycerides, blood lipids, blood viscosity, carotid ultrasound, and other related indicators were measured before and after administration to verify the actual cardiovascular protective efficacy of the milk protein peptide powder. The results are as follows:

[0107] Case 1: Male, 79 years old

[0108] Tests conducted on May 18, 2023 showed: triglycerides 2.11 mmol / L, total cholesterol 4.56 mmol / L, uric acid 424.1 μmol / L, and homocysteine ​​18.1 μmol / L; ultrasound revealed bilateral carotid intima-media thickening and multiple plaques in the left carotid artery (the largest being a mixed echogenicity of 9.3 × 2.4 mm); tests conducted on May 23, 2023 showed: whole blood high shear viscosity (200 / s) 6.63 mPa・s, whole blood medium shear viscosity (30 / s) 9.45 mPa・s, whole blood low shear viscosity (3 / s) 14.54 mPa・s, plasma viscosity 17.86 mPa・s, and erythrocyte aggregation index 9.96.

[0109] Follow-up examination on June 29, 2023: triglycerides decreased to 1.34 mmol / L (within the normal reference range of 0.56-1.71 mmol / L), total cholesterol decreased to 3.48 mmol / L, uric acid decreased to 399.3 μmol / L, and homocysteine ​​decreased to 17.4 μmol / L; ultrasound showed that the plaque at the bifurcation of the left carotid artery shrank to 2.5 × 1.8 mm, and the plaque echo changed to strong echo; blood viscosity and erythrocyte indicators were all within the normal reference range, whole blood high shear viscosity (200 / s) 5.6 mPa·s, whole blood medium shear viscosity (30 / s) 7.94 mPa·s, whole blood low shear viscosity (3 / s) 12.13 mPa·s, plasma viscosity 14.85 mPa·s, and erythrocyte aggregation index 6.97.

[0110] Case 2: Female, 73 years old

[0111] Female, tested on May 19, 2023: triglycerides 1.79 mmol / L, total cholesterol 5.51 mmol / L, uric acid 439.3 μmol / L; ultrasound showed bilateral carotid intima roughness with multiple plaques (mixed echo at the bifurcation of the right carotid artery 8.6 × 2.8 mm); blood viscosity tested on May 23, 2023: whole blood high shear viscosity (200 / s) 5.16 mPa・s, whole blood medium shear viscosity (30 / s) 7.3 mPa・s, whole blood low shear viscosity (3 / s) 11.11 mPa・s, plasma viscosity 1.47 mPa・s.

[0112] Follow-up examination on June 29, 2023: triglycerides decreased to 1.61 mmol / L (falling into the normal reference range of 0.56-1.71 mmol / L), total cholesterol decreased to 3.89 mmol / L, and uric acid decreased to 397.4 μmol / L; ultrasound showed that the mixed echo at the bifurcation of the right carotid artery had shrunk to 8.1×1.9 mm; blood viscosity indicators all decreased significantly, with whole blood high shear viscosity (200 / s) at 4.8 mPa·s, whole blood medium shear viscosity (30 / s) at 6.76 mPa·s, and whole blood low shear viscosity (3 / s) at 10.25 mPa·s.

[0113] Case 3: Female, 74 years old

[0114] Tests conducted on May 6, 2023 showed: triglycerides 2.49 mmol / L; ultrasound revealed bilateral carotid intima-media thickening with plaque formation on the left side (hyperechoic area measuring 3.3 × 2.2 mm at the origin of the left internal carotid artery), and elevated blood flow resistance index in both carotid arteries and the left vertebral artery (value > 0.75); glycated hemoglobin was 6.1% on May 5, 2023.

[0115] Follow-up examination on June 30, 2023: Triglycerides decreased to 1.89 mmol / L (within the normal reference range of ≤2.25 mmol / L); Glycated hemoglobin decreased to 5.7% (within the normal reference range of 4.0-6.0%); Ultrasound showed that the hyperechoic area at the origin of the left internal carotid artery had shrunk to 2.0×1.6 mm, the blood flow resistance index of the left carotid artery and the left vertebral artery decreased, and only the resistance index of the right common carotid artery increased.

[0116] Experimental conclusions

[0117] The milk protein peptide compressed candy prepared from the milk protein peptide powder of this invention has been clinically verified in humans to significantly reduce indicators such as triglycerides, total cholesterol, uric acid, and homocysteine, effectively improve the size and morphology of carotid artery plaques and vascular blood flow resistance, and significantly reduce whole blood high / medium / low shear viscosity and plasma viscosity. This demonstrates that the milk protein peptide powder has a clear and significant cardiovascular protective effect and is one of the core active ingredients in the composition of this invention to achieve multi-target synergistic cardiovascular protection. When combined with natto freeze-dried powder, dihydromyricetin, and functional red yeast rice powder, it can achieve a comprehensive cardiovascular protective effect.

[0118] Although embodiments of the invention have been shown and described, it will be understood by those skilled in the art that various changes, modifications, substitutions and alterations can be made to these embodiments without departing from the principles and spirit of the invention, the scope of which is defined by the appended claims and their equivalents.

Claims

1. A composition for protecting the cardiovascular system, characterized in that, Including freeze-dried natto powder, milk protein peptide powder, dihydromyricetin, and functional red yeast rice powder; The natto freeze-dried powder has a nattokinase content of 3000 FU / g, 5000 FU / g, 10000 FU / g or 20000 FU / g, the total content of VPP and IPP in the milk protein peptide powder is ≥5.0%, and the inhibition rate of the milk protein peptide powder against ACE is ≥63%.

2. The composition for protecting the cardiovascular system according to claim 1, characterized in that: By weight, the composition comprises 10-50 parts of natto freeze-dried powder, 5-30 parts of milk protein peptide powder, 1-10 parts of dihydromyricetin, and 5-25 parts of functional red yeast rice powder.

3. A composition for protecting the cardiovascular system according to claim 1 or 2, characterized in that: The natto freeze-dried powder is obtained by solid-state fermentation and vacuum freeze-drying of natto bacteria; the milk protein peptide powder is obtained by enzymatic hydrolysis, inactivation, filtration, concentration, sterilization and spray drying of milk powder or casein as raw materials; the functional red yeast rice powder is a product obtained by fermenting rice with Monascus purpureus rich in Monascus K.

4. A composition for protecting the cardiovascular system according to claim 3, characterized in that: The dihydromyricetin is derived from the fruit of the Japanese raisin tree.

5. A method for preparing the composition for cardiovascular protection according to any one of claims 1 to 4, characterized in that, Includes the following steps: S1. Raw material pretreatment: The freeze-dried natto powder, milk protein peptide powder, dihydromyricetin, and functional red yeast rice powder are sieved separately to remove impurities and set aside. S2. Mixing: The pretreated natto freeze-dried powder, milk protein peptide powder, dihydromyricetin, and functional red yeast rice powder are added into the mixing equipment in proportion and mixed evenly to obtain a mixture. S3. Post-processing: The mixture obtained in step S2 is subjected to secondary sieving and metal detection. After passing the test, the composition for protecting the cardiovascular system is obtained.

6. The preparation method according to claim 5, characterized in that: In step S1, the sieving is done through a 2.5mm sieve; in step S3, the secondary sieving is performed using a 60-mesh sieve produced for food raw materials.

7. The preparation method according to claim 5, characterized in that: In step S2, the mixing equipment is a high-efficiency mixer with a mixing speed of 100-300 r / min and a mixing time of 10-30 min.

8. The preparation method according to claim 5, characterized in that: In step S3, the metal detection involves passing the mixture through a metal detector to detect that the size of the iron-containing metal foreign objects is <2.0 mm and that no metal foreign objects exceed the control parameters.

9. The use of the composition according to any one of claims 1 to 4 in the preparation of health foods that protect vascular endothelium, dissolve thrombi, regulate blood lipids, improve vascular elasticity, or regulate blood pressure.

10. The application according to claim 9, characterized in that: The health food product is in the form of at least one of capsules, tablets, compressed candies, and solid beverages.

Images